Dr. Katherine Clifton, MD
Claim this profileWashington University School of Medicine
Studies Breast Cancer
Studies Breast cancer
12 reported clinical trials
28 drugs studied
Area of expertise
1Breast Cancer
HER2 negative
Stage IV
Stage II
2Breast Cancer
Stage IV
HER2 negative
Stage III
Affiliated Hospitals
Clinical Trials Katherine Clifton, MD is currently running
Biomarker-Driven Therapy
for Breast Cancer
This is a prospective study to assess the impact of biomarker driven, early therapeutic switching and delayed imaging with the incorporation of DiviTum® serum TK1 activity ("DiviTum® TKa") in patients with HR positive, HER-2 negative metastatic or unresectable breast cancer. Patients will receive first-line treatment with a CDK4/6 inhibitor (CDK4/6i) and endocrine therapy. All patients will have blood drawn for thymidine kinase activity (TKa) testing at baseline and at C1D15. Patients who are found to have a lack of TKa suppression at C1D15 will be recommended to switch to an alternative therapy. Patients with suppressed C1D15 TKa levels will continue on CDK4/6i and endocrine therapy until clinical progression. Patients with TKa which remains suppressed will be recommended to delay restaging scans from 24 weeks to 36 weeks. The investigators hypothesize that a patient's TKa level at C1D15 is prognostic for progression-free survival (PFS) on a CDK4/6 inhibitor and early therapeutic switching in patients with a lack of C1D15 TKa suppression will be associated with prolonged PFS.
Recruiting1 award N/A9 criteria
TK1 Activity Test
for Breast Cancer
This trial is testing a new blood test called DiviTum® TKa for patients with advanced breast cancer. The test measures a substance related to cancer, which could help doctors reduce the number of other routine tests and scans needed. DiviTum® TKa has been studied in other types of cancer patients treated with special therapies.
Recruiting1 award N/A18 criteria
More about Katherine Clifton, MD
Clinical Trial Related1 year of experience running clinical trials · Led 12 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Katherine Clifton, MD has experience with
- DiviTum® TKa Assay
- Paclitaxel
- CDK4/6 + Endocrine Therapy
- Nivolumab
- Blood Draw
- Tumor Biopsy
Breakdown of trials Katherine Clifton, MD has run
Breast Cancer
Breast cancer
Uterine Tumors
Solid Tumor Cancers
Solid Tumors
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Katherine Clifton, MD specialize in?
Katherine Clifton, MD focuses on Breast Cancer and Breast cancer. In particular, much of their work with Breast Cancer has involved HER2 negative patients, or patients who are Stage IV.
Is Katherine Clifton, MD currently recruiting for clinical trials?
Yes, Katherine Clifton, MD is currently recruiting for 5 clinical trials in Saint Louis Missouri. If you're interested in participating, you should apply.
Are there any treatments that Katherine Clifton, MD has studied deeply?
Yes, Katherine Clifton, MD has studied treatments such as DiviTum® TKa assay, Paclitaxel, CDK4/6 + Endocrine therapy.
What is the best way to schedule an appointment with Katherine Clifton, MD?
Apply for one of the trials that Katherine Clifton, MD is conducting.
What is the office address of Katherine Clifton, MD?
The office of Katherine Clifton, MD is located at: Washington University School of Medicine, Saint Louis, Missouri 63110 United States. This is the address for their practice at the Washington University School of Medicine.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.